| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 164.6 | 162.4 | 172.0 |
| Other income | 0.2 | 0.2 | 1.8 |
| Total income | 164.8 | 162.6 | 173.8 |
| Profit before exceptional items & tax | 18.8 | 15.9 | 19.1 |
| Exceptional items | -3.6 | 0.0 | 0.0 |
| Profit before tax | 15.2 | 15.9 | 19.1 |
| Net profit | 21.7 | 15.8 | 20.3 |
| Operating margin | 9.2% | 9.8% | 11.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +6.90% |
|---|---|
| Net profit, quarter on quarter | +37.30% |
| Revenue, year on year | -4.30% |
NSE results filing, NSE: WANBURY. Figures extracted from the filing.
Wanbury Ltd: key numbers
- Share price
- ₹198.70
- Market cap
- ₹694.8 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 12.4×Sector 47.3×
- Promoter holding
- 43.02%+0.00% QoQ
- FII holding
- 0.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wanbury Ltd
All →Wanbury Management Change
Wanbury Limited announced the appointment of ABK & Associates as Cost Auditor and the re-appointment of Mohan Kumar Rayana as Executive Director.
Wanbury Annual General Meeting
Wanbury Limited held its 38th Annual General Meeting on September 24, 2026. Shareholders approved financial statements, director re-appointments, and cost auditor remuneration ratification.
Wanbury Annual General Meeting
Wanbury Limited has issued a notice for its Annual General Meeting scheduled on September 24, 2026, to transact various business resolutions.
- Value
- ₹0.04 Cr
Wanbury Annual General Meeting
Wanbury Limited has scheduled its 38th Annual General Meeting for September 24, 2026. The meeting will address ordinary business, director re-appointments, and cost auditor remuneration.
Wanbury Product Launch
Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.
Wanbury Results Update
Wanbury reported Q1 FY27 financial results in a press release. The company also completed a Rs. 205 crore debt refinancing, improving its borrowing profile.
- Value
- ₹205.0 Cr